Print this page
-
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Protocol: 032405Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial.
Protocol: 132004Principal Investigator:
- Sharon Manne PhD (Rutgers University)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
- 1
- 2